CRF1 receptor antagonists have been developed to treat stress-related conditions.
|CRF 1 receptor antagonists reduced colonic transit, pain, and discomfort.
|Digestive Disease Week|
Researchers reported two trials of the Neurocrine small molecule receptor antagonist on pre-clinical models of IBS.
In one study Professor Yvette Tache, of the University of California, Los Angeles, USA, reported that a 12-fold decrease in colonic transit was found after the drug was administered intravenously to laboratory animals. The animals had previously been given a dose of CRF to mimic stress-induced exacerbation of colonic transit.
In a second study Dr Beverley Greenwood-Van Meerveld, of the Oklahoma Foundation for Digestive Research, USA, reported that the treatment was highly effective in a model of the pain and discomfort experienced by IBS patients.
Professor Tache said, "Several years of research in my laboratory have substantiated the hypothesis that the activation of CRF receptors is intimately involved in the regulation of gastrointestinal motor function under stressful conditions.
"These data, with highly selective small molecule CRF1 receptor antagonists, confirm and extend this work and provide enthusiasm to test this hypothesis in clinical trials with IBS patients."
Report Copyright: Englemed Health News at http://www.internationalmedicalnews.com